All VHIO’s Prostate Cancer Group articles
-
NewsCDK4/6 and PARP combo improves prostate cancer treatment
Researchers at VHIO have discovered a new way to overcome drug resistance in metastatic prostate cancer – by combining CDK4/6 inhibitors with follow-up therapies.